MedTrace Logo

A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

NCT03516591 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-10-12

No results posted yet for this study

Summary

An open label, Phase 1, study of AMV564 as monotherapy to assess the safety and efficacy in patients with Myelodysplastic Syndromes

Conditions

  • Myelodysplastic Syndrome (MDS)

Interventions

DRUG

AMV564 14-Day CIV

A 14-Day Continuous Intravenous Infusion regimen

Sponsors & Collaborators

  • Amphivena Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Patrick Chun, MD · Amphivena Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-22
Primary Completion
2020-07-31
Completion
2020-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03516591 on ClinicalTrials.gov